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Abstract
Introduction: Pulmonary Hypertension (PH) is a disorder of the pulmonary vasculature with high mortality and bears a large
economic burden on the healthcare system. We conducted a review of the largest inpatient database in the United States and
analyzed the trends in hospitalizations due to PH from the turn of the century (2000) to 2013 to evaluate the rate of hospitalizations
and determine the cost and mortality associated with PH.
Material and methods: We analyzed the National Inpatient Sample Database (NIS) for all patients in which PH (Primary or Secondary) or cor pulmonale was the primary discharge diagnosis (ICD-9: 416.0, 416.8 and 416.9) from 2000 to 2013. The NIS is
the largest all-payer inpatient database in the United States and contains data from approximately 8 million hospital stays each
year. The statistical significance of the difference in the number of hospital discharges, lengths of stays and associated hospital
costs over the study period was calculated.
Results: In 2000, there were 12,066 hospital admissions with the principal discharge diagnosis of pulmonary hypertension, which
increased to 13,605 admissions in 2013 (p < 0.001). The mean length of stay for PH increased from 5.89 days to 6.67 days during
this period (p = 0.04). During the same period, the hospital charges increase by 174.5% from US$ 24,973 in 2000 to US$ 68,545
in 2013 (Adjusted for inflation). The aggregate cost of hospital visits of a patient increased by 209.5% from US$ 301,324,218 in
2000 to US$ 932,554,725 in 2013.
Conclusion: The number of inpatient discharges related to PH has increased even though the number of inpatient discharges
with PAH has been reported to be lower in literature. The mean length of stay has also shown a mild increase. This increase
is associated with a significant increase in the mean and aggregate cost. These inpatient costs associated with PH contribute
significantly to the total healthcare burden. Further research on cost-effective evaluation and management of PH is required.
Key words: pulmonary hypertension, epidemiology, length of stay, hospitalisations, mortality, healthcare burden
Adv. Respir. Med. 2017; 85: 77–86

Introduction
Pulmonary hypertension (PH) is a chronic
and devastating disease characterized by progressive increases in pulmonary arterial pressure
and pulmonary vascular resistance eventually leading to right ventricular failure and death [1, 2].

It is characterized by a mean pulmonary arterial
pressure (mPAP) ≥ 25 mm Hg at rest and pulmonary arterial hypertension (PAH), a specific
subgroup of PH, has the added criteria of a pulmonary capillary wedge pressure (PCWP) ≤ 15 mm
Hg [3–5]. The World Health Organization (WHO)
currently classifies PH into 5 groups (Table 1) [6].
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Table 1. World Health Organization classification
of pulmonary hypertension (PH)
Group 1

Pulmonary arterial hypertension

Group 2

PH due to left heart disease

Group 3

PH due to lung disease and/or hypoxemia

Group 4

Chronic thromboembolic PH and other pulmonary
artery obstructions

Group 5

PH due to unclear multifactorial mechanisms

The exact prevalence of PH in the world is
unknown, and its real burden may be largely
underestimated [7]. A surveillance from the
United States Centers for Disease Control and
Prevention from 1980 to 2002, demonstrated
an increased rates of hospitalization associated
with PH with around 200,000 hospitalizations
having PH as a primary or secondary diagnosis
[8]. The severe symptoms of PH often present at
an advanced stage of the disease process leading
to a delay in diagnosis [9]. Hospitalizations related to PH also create a significant economic
burden due to the costly nature of diagnostic
procedures and medications. Most of the epidemiological information about PH is obtained
from specialized disease registries [10, 11].
With the recently expanding research into the
etiology, diagnosis and management of PH, it
is important to provide updated epidemiological data regarding the disease to aid in the
understanding of health utilization costs. Thus
we conducted a review of the largest inpatient
database in the United States and analyzed the
trends in hospitalizations due to PH from the
turn of the century (2000) to 2013.

Material and methods
The National Inpatient Sample (NIS) database was used to obtain a population-based estimate
of national trends of PH. The NIS database is
a tool developed as a part of the Healthcare Cost
and Utilization Project (HCUP), and is sponsored by the Agency for Healthcare Research and
Quality. The NIS database is the largest publicly
available all-payer inpatient care database in the
United States. The NIS database is designed to
approximate a 20% sample of US community
(nonfederal) hospitals, and is organized according to geographic region, hospital ownership,
location, teaching status, and number of beds
amongst others. The 2000 NIS database contains
a total of approximately 7.5 million records. The
78

2013 NIS database contains a total of about 7.1
million records drawn from 44 states and includes
information from 4363 hospitals. This database
is drawn from all over the United States and
represents a majority of the US population. The
immense size of the NIS database provides an
exceptional representative sample of the general
US population. In order to identify cases of PH,
the NIS database was queried for hospital data on
all discharges with ICD-9-CM primary diagnosis
codes of 416.0, 416.8 and 416.9 (Primary pulmonary hypertension, Secondary pulmonary hypertension & cor-pulmonale) from 2000 to 2013. In
2012, the NIS database was modified to draw data
from all hospitals in the hospital frame to provide
more efficient sampling while maintaining the
same strata. The NIS database provides only administrative data for analysis and patient-specific
clinical data are not available. It was assumed that
the patients were formally diagnosed with PH by
means of right heart catheterization.

Variables recorded

Recorded patient demographics include age
and gender. Hospital characteristics included bed
size (small, medium, and large) and owner (government, private non-profit or private for-profit) and
the region of location (Northeast, Midwest, South
& West). Hospital bed size varies depending on the
hospital’s location and teaching status. Small hospitals range from 1 to 299 beds, medium hospitals range from 50 to 499 beds, and large hospitals
range from 100 to 500 or more beds. The payer
status for all admissions was also considered and
divided into categories of Medicare, Medicaid,
private insurance, uninsured, and other. “Hospital
Charges” are defined as the amount the hospital
charged for the patient’ s entire hospital stay, but
it does not include professional (physician) fees.
As per NIS, “aggregate charges” or the national
“bill” is defined as the sum of all charges for all
hospital stays in the United States and “length of
stay” as the number of nights the patient remained
in the hospital per stay.

Statistics

The trends for average length of stay, mean
total charges, mortality and total number of discharges specifically for the diagnosis of PH were
plotted and analyzed from 2000 to 2013. The
frequency of discharges with PH was calculated
by dividing the annual number of discharges with
a primary discharge diagnosis of PH by the total
number of all discharges listed in the NIS for each
year. The Pearson Chi-Square test was used to
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compare proportions between 2000 and 2013.
All statistical calculations were computed using
SAS (version 9.4, The SAS Institute, NC). HCUP
provided consolidated data for all codes of PH
(416.0,416.8 and 416.9). The aggregate charges
(“ the national bill ”) were calculated by summing the individual ICD-9 codes (416.0,416.8
and 416.9). Annual charges reported are the
raw charges adjusted for the long-term average health-care annual inflation rate (Bureau
of Labor Statistics: http:// data.bls.gov/) such
that all dollar values relate to 2013 dollars.
The temporal trend in length of stay and hospital charges with PH observed from 2000 to
2013 was assessed via polynomial regression,
in which the most appropriate functional form
for the trend was assessed by examination of
regression diagnostic plots. A linear shape plot
was determined to be appropriate for discharge
count, length of stay, and mortality. The statistical significance of the trend was determined
via Spearman’s correlation technique to obtain
p-values. P-value < 0.05 was considered to be
statistically significant.
In addition to the percentages available adjacent to the data in the tables, the frequency per
10,000 admissions for each variable was calculated. Thus the numbers are a representation of
the density of patients admitted/discharged with
PH compared with the total number of hospital
discharges per category. Each frequency was calculated by dividing the number of patients with
pulmonary hypertension by the total discharges
in a specific categorical variable for each year
and multiplying the number by 10,000. Rates
that have been compared over time using Poisson
regression, which yields relative rates (RRs) that
express the ratio of rate per 10,000 in 2013 to that
in 2000. P-value of < 0.05 was considered to be
statistically significant.

Results
Results characterizing the trends in PH related
hospitalizations, length of stay, cost, mortality and
discharges have been outlined in Tables 2 and 3.

Number and cost of PH discharges

From 2000 to 2013, the total number of hospital discharges with the principal diagnosis of
PH increased by 12.8% from 12,066 to 13,605
(p < 0.001). Thus the frequency of hospital discharges with PH as the principal diagnosis increased from 3.42 per 10,000 discharges to 3.82 per
10,000 discharges (RR = 1.12, 95% CI: 1.09–1.15;

p < 0.001). The linear trend of PH admissions and
discharges also showed a statistically significant
increase from 2000 to 2013 (R² = p) (Fig. 1).
The average length of stay of a PH admission
showed an increase from 5.89 days in 2000 to 6.67
days in 2013 (Fig. 2). The aggregate cost of hospital visits of a patient with the principal diagnosis
of PH increased 209.5% from US$ 301,324,218
in 2000 to US$ 932,554,725 in 2013. The mean
hospital charges per patient increased 174.5%
from US$ 24,973 in 2000 to US$ 68,545 in 2013
(Adjusted for inflation).

Patient characteristic by age

The highest number of patient discharges in
both 2000 and 2013 was noted in the 65–84 age
group. The frequency of discharges was noted to
be higher in the 45–64 age group in 2000 (5.74
per 10,000 discharges) while it was highest in the
65–84 age group in 2013 (5.56 per 10,000 discharges). The increase in the frequency of discharge
rates was most remarkable in age groups 65–84
and > 85 years. A drop in the rate of discharges
was noted in the age groups 18–44 (R = 0.85,
95%CI: 0.80–0.90; p < 0.001) and 45–64 (RR =
0.90, 95% CI: 0.86–0.94; p < 0.001).

Patient characteristics by sex

The number of PH admissions and discharges
was noted to be greatest in females both in 2000
and 2013, increasing from 3.7 per 10,000 discharges in 2000 to 4.41 per 10,000 discharges in 2013.
(RR = 1.19, 95% CI: 1.16–1.23; p < 0.001). The
increase for males did not show a statistically
significant rise and increased from 3 per 10,000
discharges in 2000 to 3.03 per 10,000 discharges
in 2013 (p = 0.74).

Patient characteristics by payer group

The relative frequency of PH discharges
increased for all types of payer groups except
Medicaid over this 13-year period. The highest
absolute number of PH discharges was in the
Medicare group in both 2000 and 2013, which
increased from 4.93 per 10,000 discharges in 2000
to 5.71 per 10,000 discharges in 2013 (RR = 1.16,
95% CI: 1.12–1.20; p < 0.001). While in 2000, the
frequency of discharges from the Medicare group
was higher (2.87 per 10, 000 discharges), the drop
of discharges from Medicare group meant that the
frequency of discharge of patients with Private
insurance was higher in 2013 (2.66 per 10,000
discharges). There was a modest increase in the
number of discharges in both the uninsured and
other payer groups as noted in Table 1.
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Table 2. Trends in characteristics of PH related hospitalizations from 2000 to 2013
2000
PH
(N, )

2013
PH
(N, )

2000
Total
(N, )

2013
Total
(N, )

PH per
10,000
admissions
in 2000

PH per
10,000
admissions
in 2013

RR (95% CI)

P-value

12,066

13,605

35,300,425

35,597,792

3.42

3.82

1.12
(1.09–1.15)

< 0.001

<1

146

175

4,541,823

4,232,808

0.32

0.41

1.29 (1.03–1.60)

0.024

1–17

234

415

1,626,291

1,393,028

1.44

2.98

2.07 (1.76–2.43)

< 0.001

18–44

2,216

1,710

9,617,360

8,727,809

2.3

1.96

0.85 (0.80–0.90)

< 0.001

45–64

4,110

4,520

7,159,251

8,753,270

5.74

5.16

0.90 (0.86–0.94)

< 0.001

65–84

4,637

5,330

9,855,601

9,581,434

4.7

5.56

1.18 (1.14–1.22)

< 0.001

> 85

723

1,455

2,493,840

2,906,938

2.9

5.01

1.73 (1.58–1.89)

< 0.001

Male

4,318

4,585

14,372,338

15,154,195

3

3.03

1.01 (0.97–1.05)

0.74

Female

7,744

9,020

20,920,986

20,436,357

3.7

4.41

1.19 (1.16–1.23)

< 0.001

Medicare

6,294

7,990

12,763,012

13,986,550

4.93

5.71

1.16 (1.12–1.20)

< 0.001

Medicaid

1,667

1,825

5,814,171

7,417,129

2.87

2.46

0.86 (0.80–0.92)

< 0.001

Private
Insurance

3,456

2,890

13,787,690

10,851,650

2.51

2.66

1.06 (1.01–1.12)

< 0.05

Uninsured

324

505

1,724,382

2,070,848

1.88

2.44

1.30 (1.13–1.50)

< 0.001

Other

306

390

1,070,236

1,216,485

2.86

3.20

1.12 (0.97–1.30)

0.13

Low
Median
income for zip ($0–35,999)
code

*

4,160

*

10,199,933

*

4.08

Not low
($36,000+)

*

9,120

*

24,599,165

*

3.71

Government

1,837

2,020

4,608,704

4,291,755

3.99

4.71

1.18 (1.11–1.26)

< 0.001

Private,
not-for-profit

9,050

9,920

26,471,999

26,111,822

3.42

3.80

1.11 (1.08–1.14)

< 0.001

Private,
for-profit

1,179

1,665

4,219,722

5,194,215

2.79

3.21

1.15 (1.06–1.24)

< 0.001

Small

1,148

1,495

4,049,244

4,884,892

2.84

3.06

1.08 (0.10–1.17)

0.05

Medium

2,955

3,205

9,621,509

9,512,936

3.07

.3.37

1.10 (1.04–1.15)

< 0.001

Large

7,945

8,905

2,1578,915

21,199,964

3.68

4.2

1.14 (1.11–1.18)

< 0.001

Northeast

2,096

2,405

7,009,155

6,730,965

2.99

3.57

1.19 (1.13–1.27)

< 0.001

Midwest

3,072

3,275

8,221,274

8,004,912

3.74

4.09

1.09 (1.04–1.15)

< 0.001

South

4,566

4,900

13,340,212

13,818,031

3.42

3.55

1.04 (0.10–1.08)

0.085

West

2,332

3,025

6,729,784

7,043,884

3.47

4.30

1.24 (1.17–1.31)

< 0.001

Categorical
Variable
All discharges
Mean age
(years)
Age group
(years)

Sex

Payer

Owner

Bed Size

Region

80
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Table 3. Trends in characteristics of PH related hospitalizations & discharges from 2000 to 2013

Total number of discharges
Length of Stay
Charges (mean, adjusted for inflation)
Total charges (adjusted for inflation)
Mortality
Routine Discharges

2000
PH

2013
PH

RR(CI)

P-value

12,066

13605

–

< 0.01

5.89 days

6.67 days

–

0.04

$24973

$68545

–

–

$301,324,218

$932,554,725

–

–

807 (6.69%)

620 (4.56%)

0.70 (0.63–0.77)

< 0.001

8232 (68.23%)

7835 (57.59%)

0.90 (0.88–0.92)

< 0.001

Another short term hospital

396 (3.28%)

585 (4.30%)

1.30 (1.14–1.47)

< 0.001

Nursing Home or Rehabilitation

1094 (9.07%)

1760 (12.94%)

1.38 (1.28–1.48)

< 0.001

Home Health Care

1490 (12.35%)

2690 (19.77%)

1.50 (1.42–1.60)

< 0.001

46 (0.38%)

105 (0.77%)

2.02 (1.43–2.85)

< 0.001

Against medical advice

Figure 1. Trends in in-hospital discharges

Pulmonary Hypertension discharges by
hospital ownership, characteristics and
region

There was a rise in the number of PH discharges from all 3, hospital owner categories from
2000 to 2013 (Government, Private (Not-for-profit) and Private (For-profit). The overall highest
number of discharges were seen from Private,
not-for-profit hospitals. The highest increase in
frequency was seen in discharges from Government hospitals (RR= 1.18, 95% CI: 1.11–1.26; p <
0.001). In 2000 a patient with PH was more likely

to be admitted and discharged from a hospital
with a large number of beds (65.85%) as compared to hospital with medium or small number of
beds, and this trend continued in 2013 (69.45%).
The South had the highest number of both
PH discharges and total discharges in 2000 as well
as 2013. Even then, the increase in the frequency
of discharge in the South from 2000 to 2013 was
not statistically significant (p = 0.085). On the
contrary, the Midwest had the highest frequency
of PH discharges in 2000 with 3.74 per 10,000
discharges while in 2013 it was highest in the
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Figure 2. Trends in length of stay

Figure 3. Trends in mortality

West with 4.3 per 10,000 discharges. The total
number and frequency of discharges in all regions
except the South showed a statistically significant
increase (Table 1).

Pulmonary hypertension discharges with
mortality rates and discharge disposition

The percent mortality of patients admitted
and discharged with a principal diagnosis of PH
82

decreased from 6.69% in 2000 to 4.56% in 2013
with a statistically significant decrease in the linear trend (R² =; p < 0.01) (Fig. 3). The number
of routine discharges decreased from 68.23% to
57.59% of the total discharges. On the other hand,
discharges from the hospital to nursing home and
rehabilitation increased from 9.07% to 12.94%
(RR = 1.38, 95 CI: 1.28–1.48; p < 0.001). Also
notable was the fact patients discharged with

www.journals.viamedica.pl

Rutuja R. Sikachi et al., Nationwide trends in inpatient admissions of pulmonary hypertension

Figure 4. Trends graph in mortality of pulmonary hypertension and cost along with sentinel events in management of pulmonary arterial hypertension

home health care increased from 12.35% of total
discharges in 2000 to 19.77% of total PH discharges
in 2013 (RR= 1.50, 95% CI: 1.42–1.60; p < 0.001).

Discussion
Pulmonary hypertension continues to be
a challenging disease to diagnose and manage
due to its heterogeneous etiology and complex
pathogenesis. There appears to be a growing
number of diagnoses of PH, possibly due to the
greater awareness of this once considered, rare
disease or due to better screening and diagnostic
availability i.e. right heart catheterizations and
echocardiography. However determining the
exact epidemiology has proven challenging due
to a lack of global consensus on prevalence. In
the United Kingdom, a prevalence of 97 cases per
million with a female: male ratio of 1.8 has been
reported and in the United States the age-standardized death rate ranges between 4.5 and 12.3
per 100,000 population [12]. The United States’
national inpatient database provides valuable
information, exploring aspects of patient characteristics, epidemiology as well as providing
a snapshot of economic burden of this disease.

Discharges and length of stay

Our study demonstrated that in the national
trend of the United States; there was a statistically significant increase in the overall number
of hospitalizations for PH from 2000 through to
2013. This was in spite of the fact that a recent
study reported a decline in the number of hospitalizations associated with PAH (Group 1) alone
from 2001 through 2012 [13]. This would indicate

that the rise in the number of hospitalizations due
to PH can actually be attributed to an increase
in admissions due to secondary causes of PH
i.e. WHO Group 2–5 PH. A review of literature
did not yield any comparative data in terms of
hospital admissions for all WHO groups of PH.
Most available data in literature focuses of WHO
Group I PAH, possibly due to the fact that there
is available pharmacological treatment.
This overall increase in hospitalizations may
be attributed to a number of causes. One explanation may be the increased awareness about
PH in the modern management era. While PH
was once known as an orphan disease [8], new
effective therapies to treat PAH are now available.
Primary or idiopathic PH was once considered
a rare disease that affected young women at the
time of the initial National Institutes of Health
(NIH) registry [14]. Thus older patients might
have often been not considered candidates for
diagnosis of PH at that time. This fact has likely
changed thus leading to an increase in the diagnosis of PH especially in that subgroup (Group
I PH). This is reinforced by the fact that the number of admissions in the age group > 85 years has
shown a significant rise from 2000 to 2013. Thus
increased awareness has likely played a major
role in increasing the total number of patients
diagnosed with PH.
Another contributing factor is the wide spread use of doppler echocardiography and other
imaging modalities in the community leading
to increase in the diagnosis of PH. Papolos et al.
recently showed that between 2001 and 2011, the
absolute volume and incidence of echo increased
at an average annual rate of 3.41% and 3.04%
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respectively [15]. A study in 2009 concluded
that the use of computed tomography (CT) had
doubled and the use of magnetic resonance imaging (MRI) had tripled in the 10 years preceding
the study [16]. Both these tests demonstrate an
enlarged pulmonary arterial size or other radiographical features of PH, which may lead to the
diagnosis of PH. The rise of hospitalizations could
also be attributed to the fact that previously diagnosed PH patients might be readmitted due to an
overall decrease in mortality as discussed later.
Our study also demonstrated a significant,
13% increase of length of hospital stay from
2000 to 2013. This may seem counterintuitive
as our diagnostic and treatment modalities have
advanced over the analyzed time period. The
exact reason for the increase in length of stay is
unknown however it may be attributed to possible
complications associated with advanced stages
of PH disease. A German study by Wilkens et
al. demonstrated that the average length of stay
of PAH a patient was 11.8 ± 28.2 days [17]. As
the availability of advanced diagnostics i.e. right
heart catheterization become available in all
healthcare centers the increase in the number of
inpatient diagnostic tests could also contribute
to the increased length of stay in these patients.
Another recent study noted an increased frequency of cardiogenic shock, cardiac dysrhythmias,
acute respiratory failure and renal failure in patients with PH [13], which in turn may lead to an
increased length of stay.

Age characteristics and payer status

There was a trend towards admission of
patients greater than 65 years of age that is in
line with all recent studies that found a shift in
diagnosis of PH to an older age [13, 18–20]. Most
patients continued to be women in both 2000 and
2013. There was no statistically significant increase in the frequency of men with hospitalizations
due to PH in 2013 compared to 2000. In terms of
payer status, we found that the highest absolute
number of PH discharges was in the Medicare group in both 2000 and 2013. This is likely due to the
fact that 44.4% of the patients in 2000 and 49.80%
of the patients in 2013 were above the age of 65.
Although there was a decrease in the number of
PH patients with private insurance, this was likely
a reflection of the national trend in 2013 where
lesser patients had private insurance as compared
to patients in 2000. The relative frequency of PH
with private insurance actually showed a small
increase. We noted that patients with PH were
more likely to be admitted to private, not-for-pro84

fit hospitals. We also observed that patients with
PH were more likely to be admitted to hospitals
with a large number of beds as compared to hospitals with a medium or small number of beds.
This might be due to the fact that tertiary care
hospitals, which usually have large number of
beds, are better equipped to deal with the complex
course of a pulmonary hypertension patient. In
terms of regional distribution, the southern part of
United States had the highest number of absolute
discharges of PH patients in both 2000 and 2013.
On the other hand, the Midwestern United States
had the highest frequency.

Health utilization costs

We found that the aggregate hospital charges adjusted for inflation for patients with PH
increased 2.1 fold from 2000 to 2013. There are
several possible explanations for this rise. As
noted earlier, there is an increased frequency
of complications in patients with PH. Increased
complications leads to an increased length of stay
and an associated increased cost of hospitalization. There has also been a tremendous rise in the
usage of diagnostic modalities amongst patients
admitted to the hospitals in United States in the
last decade [15, 16]. This increased use of diagnostic modalities is associated with an increased
healthcare expenditure.
The approval of new, expensive drugs targeted against WHO Group I PAH such as Epoprostenol, Bosentan, Sildenafil, Ambrisentan, Tadalafil
and Riociguat have likely also contributed to the
increased healthcare burden while the patients
are admitted to the hospital (Fig. 4). The European
Society of Cardiology’s practice guideline on PAH
released in 2004 redefined PAH as per the new
clinical classification and described an algorithm
of various investigative tests, procedures and evidence-based treatment. This likely contributed to
an accurate diagnosis and management of PAH at
the expense of increasing healthcare costs [21].
A study by Kirson et al. that analyzed a private
insurance database from 2002–2007 demonstrated as compared to the general population
patients with PAH had substantially higher costs
and comorbidity resulting in 40% of excess costs
associated with management and treatment of
PAH patients [22]. On the contrary, management
of PH WHO Group II & III is focused on treatment
of the underlying disease. Newer therapies for
these diseases such as heart failure, chronic lung
disease and other connective tissue disorders also
contribute to an increased cost of hospitalization.
This includes the use of invasive modalities and
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implantable cardiac devices for cardiac condition
in patients with Group II PH and the use of novel
drugs in the treatment of patients with Group
III PH. Our results are consistent with previous
studies that have found an increased length of
hospitalization and an increased inpatient cost
for PH related hospitalizations [13].
As our analysis focuses on data from the
United States, the perspective provided is that of
a multi-payer health system that is semi privatized. It is important to understand the dynamics
of PH admission and the health utilization costs
in single payer health systems. In a study by Vaid
et al. [23] on Ontario in Canada, it was noted that
there were higher hospitalization costs, nearly
fivefold, in the cohort of PAH patients who died
due to their disease as compared those who survived. Though this is a small sample size we are
able to see that costs are high, and that patients
with more severe disease have greater health
utilization costs regardless of whether they were
hospital or pharmaceutical related. There is yet
to be comprehensive data on PH as a whole in
a single payer system. From the data put forth,
emphasis of PH should be placed on early diagnosis and management. In a study by Sikirica
[24], it was found that subjects with evidence of
PAH had substantively high health care costs.
Medical costs appeared to decrease following
medication use for PAH, but with a concomitant
increase in pharmacy costs. Cost of PH diagnosis
and management is detrimental as there is a correlation between socioeconomic status of patients
with clinical outcomes and disease severity at
presentation in PH [25, 26].

Mortality

Our analysis showed that there was a 23%
reduction in mortality in 2013 as compared to
2000 amongst patients hospitalized with diagnosis of PH. The mortality rate reduced from 6.69%
in 2000 to 4.56% in 2013 (Fig. 4). The progressive
decrease in mortality has been heralded by newer
therapies for Group 1 and Group 4 PH and improvement in treatment options for chronic lung
and chronic heart disease. An early diagnosis
due to the increased use of imaging modalities,
follow up at dedicated PH centers and close outpatient follow up have all likely contributed to
this reduced mortality. A review of the discharge
disposition revealed that there was a significant
increase of the number of discharges with home
health care from 2000 to 2013. This possibly reflects the multiple co-morbidities as well as the
complex nature of the patient’s illness. This also

contributes significantly to the increased burden
on healthcare expenditure. A significant increase
was also seen in the number of patients discharged to a nursing home or rehabilitation facility.
The increases in discharges to a nursing home is
consistent with the fact that more patients admitted for PH are above the age of 85 and thus are
more likely to be nursing home residents. Patients
with increased length of stay and associated physical debilitation are also more likely to require
rehabilitation facilities before discharge back to
home or nursing home.

Limitations
The design of this study and the nature of
the NIS database set leads to some important
limitations. As this is an administrative data set,
it reflects the coding practices of each institution.
Thus it is likely that these results underestimate the actual number of patients admitted and
discharged with the diagnosis of PH. It is likely
that patient’s discharges may have been coded
with an alternative primary diagnosis such as
heart failure, hypoxemia, chronic lung diseases
or other underlying connective tissue disorders
with PH as a secondary diagnosis. For our study
these patients were excluded as they might have
been admitted for a non-cardiopulmonary manifestation and carried a secondary diagnosis of PH.
With the use of the NIS database it would also be
hard to calculate or determine if patients were
admitted from the emergency room or transferred
from community hospitals to expert PH centers.
While it is plausible to think that hospitals were
not able to manage these patients and thus transferred the patient to a tertiary center, it reflects
real world practice. In addition, this data set does
not control for errors during the entry of the data.
Also, patient specific clinical information was not
obtainable which thereby limited the demographic
data presented in the research. Results of right heart
catheterization were not available for these patients
and thus adherence to the diagnostic criteria for PH
could not be confirmed. Further studies analyzing
hospital coding practices may clarify these concerns. In addition, the NIS data set does not provide
details regarding the patient or the hospital, which
could help us, explain the rise or decline in the
hospital discharges and associated costs.

Conclusion
In conclusion, PH is an escalating concern
in the United States healthcare system. This is
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demonstrated by the significant increase in the
hospital cost associated with PH admissions
from 2000 to 2013. Future studies analyzing the
diagnostic modalities, algorithms and treatment
practices of physician’s treating PH are necessary to reduce the burden it has on the healthcare
system.
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